SMT201600053B - Composti di 1 h-indazolq-3-carbossammide come inibitori della glicogeno sintasi chinasi 3 beta - Google Patents

Composti di 1 h-indazolq-3-carbossammide come inibitori della glicogeno sintasi chinasi 3 beta

Info

Publication number
SMT201600053B
SMT201600053B SM201600053T SM201600053T SMT201600053B SM T201600053 B SMT201600053 B SM T201600053B SM 201600053 T SM201600053 T SM 201600053T SM 201600053 T SM201600053 T SM 201600053T SM T201600053 B SMT201600053 B SM T201600053B
Authority
SM
San Marino
Prior art keywords
synthasis
indazolq
glycogenous
carbossamide
chinase
Prior art date
Application number
SM201600053T
Other languages
English (en)
Italian (it)
Inventor
Maria Alessandra Alisi
Nicola Cazzolla
Patrizia Dragone
Guido Furlotti
Caterina Maugeri
Rosella Ombrato
Francesca Mancini
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of SMT201600053B publication Critical patent/SMT201600053B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SM201600053T 2012-02-21 2016-02-23 Composti di 1 h-indazolq-3-carbossammide come inibitori della glicogeno sintasi chinasi 3 beta SMT201600053B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12156292 2012-02-21
PCT/EP2013/052400 WO2013124158A1 (en) 2012-02-21 2013-02-07 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors

Publications (1)

Publication Number Publication Date
SMT201600053B true SMT201600053B (it) 2016-04-29

Family

ID=47739223

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600053T SMT201600053B (it) 2012-02-21 2016-02-23 Composti di 1 h-indazolq-3-carbossammide come inibitori della glicogeno sintasi chinasi 3 beta

Country Status (26)

Country Link
US (3) US9611249B2 (de)
EP (1) EP2817302B1 (de)
JP (1) JP6141331B2 (de)
KR (1) KR20140130124A (de)
CN (1) CN104093712B (de)
AR (1) AR090086A1 (de)
AU (1) AU2013224302B2 (de)
BR (1) BR112014018655B1 (de)
CA (1) CA2860250C (de)
CY (1) CY1117469T1 (de)
DK (1) DK2817302T3 (de)
EA (1) EA024939B1 (de)
ES (1) ES2564961T3 (de)
GE (1) GEP20166489B (de)
HR (1) HRP20160125T1 (de)
HU (1) HUE026893T2 (de)
IL (1) IL233824A (de)
ME (1) ME02353B (de)
MX (1) MX351287B (de)
PL (1) PL2817302T3 (de)
RS (1) RS54567B1 (de)
SG (2) SG11201403602WA (de)
SI (1) SI2817302T1 (de)
SM (1) SMT201600053B (de)
UA (1) UA112564C2 (de)
WO (1) WO2013124158A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564033T3 (es) 2012-02-21 2016-03-17 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A. Utilización de compuestos de 1H-indazol-3-carboxamida como inhibidores de la glucógeno sintasa cinasa 3 beta
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
MA39763A (fr) 2014-03-20 2017-01-25 Samumed Llc Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci
EP3464266B1 (de) 2016-06-01 2021-10-20 Bayer Animal Health GmbH Zur behandlung und vorbeugung von allergischen und/oder entzündlichen erkrankungen bei tieren geeignete substituerte indazole
EP3468960B1 (de) * 2016-06-08 2022-03-23 GlaxoSmithKline Intellectual Property Development Limited Chemische verbindungen als atf4-pfad-hemmer
BR112020017087A2 (pt) * 2018-02-23 2020-12-22 Samumed, Llc Indazol-3-carboxamidas substituídas 5-heteroarila e preparação e uso das mesmas
MD3790873T2 (ro) * 2018-05-07 2022-07-31 Acraf Compuși 1H-indazol-3-carboxamidici în calitate de inhibitori ai glicogensintazkinazei 3-beta
AU2019280693B2 (en) 2018-06-05 2024-10-10 Actuate Therapeutics Inc. Methods of treating malignant lymphoproliferative disorders
AU2019337612A1 (en) 2018-09-13 2021-05-13 Bristol-Myers Squibb Company 1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1)
CN112673001B (zh) 2018-09-13 2024-06-25 百时美施贵宝公司 作为激酶抑制剂的吲唑甲酰胺
US20240051939A1 (en) * 2020-12-08 2024-02-15 Disarm Therapeutics, Inc. Benzopyrazole inhibitors of sarm1

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08502741A (ja) 1992-11-05 1996-03-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5−ht▲下4▼レセプターアンタゴニスト用のピペリジン誘導体
IT1291569B1 (it) * 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
WO2004014922A1 (en) * 2002-08-10 2004-02-19 Astex Technology Limited 3-(carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors
GB0218625D0 (en) * 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
ITMI20030287A1 (it) * 2003-02-18 2004-08-19 Acraf Indazolammidi dotate di attivita' analgesica metodo, per
ITMI20030972A1 (it) 2003-05-15 2004-11-16 Acraf Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende.
WO2005014554A1 (en) * 2003-08-08 2005-02-17 Astex Therapeutics Limited 1h-indazole-3-carboxamide compounds as mapkap kinase modulators
GB0414438D0 (en) * 2004-06-28 2004-07-28 Syngenta Participations Ag Chemical compounds
AR052660A1 (es) * 2005-01-21 2007-03-28 Astex Therapeutics Ltd Derivados de pirazol para inhibir la cdk's y gsk's
EP1692939A1 (de) * 2005-02-19 2006-08-23 Bayer CropScience S.A. Pestizide substituierte Piperidine
SG182187A1 (en) * 2007-06-08 2012-07-30 Abbott Gmbh & Co Kg 5-heteroaryl substituted indazoles as kinase inhibitors
UA99927C2 (uk) 2007-11-12 2012-10-25 Ацьенде Кимике Риуните Анджелини Франческо А.Чи.Р.А.Ф. С.П.А. Медикамент, який є активним при невропатичному болі
US8377968B2 (en) * 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US7947728B1 (en) * 2009-11-11 2011-05-24 Hoffmann-La Roche Inc. Indole and indazole analogs as glycogen synthase activators

Also Published As

Publication number Publication date
WO2013124158A1 (en) 2013-08-29
MX2014009297A (es) 2014-08-27
IL233824A (en) 2016-09-29
MX351287B (es) 2017-10-09
US20170157121A1 (en) 2017-06-08
DK2817302T3 (en) 2016-03-21
AU2013224302B2 (en) 2017-03-30
EP2817302B1 (de) 2015-12-30
BR112014018655A2 (de) 2017-06-20
JP2015506993A (ja) 2015-03-05
HUE026893T2 (en) 2016-07-28
EA201491449A1 (ru) 2014-11-28
HRP20160125T1 (hr) 2016-03-11
AU2013224302A1 (en) 2014-07-17
SG11201403602WA (en) 2014-07-30
ME02353B (de) 2016-06-20
GEP20166489B (en) 2016-06-10
RS54567B1 (sr) 2016-06-30
SG10201701649YA (en) 2017-04-27
US20170174657A1 (en) 2017-06-22
KR20140130124A (ko) 2014-11-07
US10160746B2 (en) 2018-12-25
BR112014018655B1 (pt) 2022-02-08
AR090086A1 (es) 2014-10-15
CA2860250A1 (en) 2013-08-29
SI2817302T1 (sl) 2016-03-31
IL233824A0 (en) 2014-09-30
CN104093712A (zh) 2014-10-08
CA2860250C (en) 2020-11-10
BR112014018655A8 (pt) 2017-07-11
HK1203930A1 (zh) 2015-11-06
EP2817302A1 (de) 2014-12-31
JP6141331B2 (ja) 2017-06-07
US9611249B2 (en) 2017-04-04
PL2817302T3 (pl) 2016-06-30
EA024939B1 (ru) 2016-11-30
US20150057294A1 (en) 2015-02-26
CN104093712B (zh) 2016-11-09
UA112564C2 (uk) 2016-09-26
ES2564961T3 (es) 2016-03-30
CY1117469T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
SMT201700094B (it) Composto di pirazina carbossammide
SMT201700109B (it) Inibitori di istone demetilasi
SMT201600053B (it) Composti di 1 h-indazolq-3-carbossammide come inibitori della glicogeno sintasi chinasi 3 beta
SMT201600108B (it) Derivato di pirazochinolina come inibitori di pde9
SMT201700111B (it) Eterociclilammine come inibitori di pi3k
SMT201700052B (it) 2-(azaindol-2-il)benzimidazoli come inibitori di pad4
EP2842955A4 (de) Trk-hemmende verbindung
EP2683693A4 (de) Ror-gamma-t-hemmer
HRP20170112T8 (hr) Supstituirani spojevi piridin-2-karboksamida kao kinazni inhibitori signalne regulacije apoptoze
LT3181567T (lt) Pirazolpirimidino junginiai kaip kinazės slopikliai
HUE036259T2 (hu) Inhibitor vegyületek
EP2736491A4 (de) Bepotastin-zusammensetzung
IL227764A0 (en) Pyrrolotriazinone derivatives as pi3k inhibitors
EP2675909A4 (de) Glucosylstevia-zusammensetzung
CO7030959A2 (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
EP2720561A4 (de) Stevia-zusammensetzung
SMT201600114B (it) Inibitori di beta-secretasi
HRP20150709T8 (hr) Kompenzacijski spoj
CO6960542A2 (es) Polimorfos de inhibidores de cinasas
EP2713762A4 (de) Stevia-zusammensetzung
HRP20180450T1 (hr) Heterobiciklični spojevi kao inhibitori beta-laktamaze
EP2877458A4 (de) Cystathionin-y-gamma-lyase (cse)-hemmer
SMT201600328B (it) Nuovi composti come inibitori di diacilglicerolo aciltransferasi
IL228108A0 (en) Triazolopyridine compounds as pim kinase inhibitors
DK3489226T3 (da) Hæmmere for natriumglucose-cotransporter 1